All In Biotech

Drug Trial Radar · NCT00211276

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

A Phase II Multicenter Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non-Hodgkins Lymphoma.

Last checked: Nov 20, 2026Latest source record: Mar 14, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Planned (sponsor's estimate)

Start

Mar 2005

Primary completion

Jan 2007

Study completion Feb 2007

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Sep 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical research study is to find out if the study drug, ONTAK (denileukin diftitox), can shrink or slow the growth of B-cell non-Hodgkin's lymphoma (NHL) in patients whose disease has not responded to prior treatments, or has relapsed after an initial response to prior treatments. The safety of treatment with ONTAK will also be studied. The hypothesis is that patients with relapsed or refractory B-cell NHL and mild to moderate myelosuppression treated with ONTAK at a new dosing regimen will respond sufficiently to warrant further study.

Conditions

  • Lymphoma, B-Cell

Interventions

  • ONTAK (denileukin diftitox)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Response will be evaluated by CT or MRI scans at baseline, every 8 weeks while on therapy, and every 3 months after therapy, using standard response criteria defined by Cheson et al.

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Tower Cancer Research Foundation

    Beverly Hills, California

  • Pacific Coast Hematology/Oncology

    Fountain Valley, California

  • University of California, Los Angeles

    Los Angeles, California

  • Emory University

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Siouxland Hematology-Oncology

    Sioux City, Iowa

  • Washington University Siteman Cancer Center

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • St. Vincent's Comprehensive Cancer Center

    New York, New York

  • Case Comprehensive Cancer Center

    Cleveland, Ohio

  • The Western Pennsylvania Hospital

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.